相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia
A. M. Eiring et al.
LEUKEMIA (2015)
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
Matthew S. Zabriskie et al.
CANCER CELL (2014)
High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing
Richard Bourgon et al.
CLINICAL CANCER RESEARCH (2014)
A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia
Leyuan Ma et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
The Antiproliferative Activity of Kinase Inhibitors in Chronic Myeloid Leukemia Cells Is Mediated by FOXO Transcription Factors
Francesca Pellicano et al.
STEM CELLS (2014)
Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors
E. Traer et al.
LEUKEMIA (2012)
Pushing the limits of targeted therapy in chronic myeloid leukaemia
Thomas O'Hare et al.
NATURE REVIEWS CANCER (2012)
PI3K-AKT-FoxO axis in cancer and aging Preface
Guri Tzivion et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2011)
FoxO transcription factors; Regulation by AKT and 14-3-3 proteins
Guri Tzivion et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2011)
BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance
Hilmar Quentmeier et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2011)
Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice
Michael G. Kharas et al.
BLOOD (2010)
Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells
Takeru Nambu et al.
CANCER SCIENCE (2010)
BCR-ABL Gene Expression Is Required for Its Mutations in a Novel KCL-22 Cell Culture Model for Acquired Resistance of Chronic Myelogenous Leukemia
Hongfeng Yuan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
TGF-β-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
Kazuhito Naka et al.
NATURE (2010)
Constitutively Nuclear FOXO3a Localization Predicts Poor Survival and Promotes Akt Phosphorylation in Breast Cancer
Jie Chen et al.
PLOS ONE (2010)
Efficacy of Imatinib Dose Escalation in Patients With Chronic Myeloid Leukemia in Chronic Phase
Hagop M. Kantarjian et al.
CANCER (2009)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers
T. Goto et al.
BRITISH JOURNAL OF CANCER (2008)
Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines
Pedro P. Medina et al.
HUMAN MUTATION (2008)
The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression
Rosaline C. -Y. Hui et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA working party on chronic myeloid leukemia
Simona Soverini et al.
CLINICAL CANCER RESEARCH (2006)
Multiple roles of FOXO transcription factors in mammalian cells point to multiple roles in cancer
Karen C. Arden
EXPERIMENTAL GERONTOLOGY (2006)
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
A Burchert et al.
LEUKEMIA (2005)
Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty
BMT Burgering et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2003)
Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy
A Hochhaus et al.
LEUKEMIA (2002)
分享论文
